NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SY
So-Young International Inc.
There isn't enough reported data to score SY yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
SY's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SY PE Valuation
SY has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SY Forward outlook
There aren't enough analyst estimates for SY to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SY on earnings quality, reporting a profit while its opponent remains loss making.
SY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.28 | +$0.46 |
| Q1 2026 | -$0.29 | +$0.39 |
| Q4 2025 | -$0.27 | +$0.39 |
| Q3 2025 | -$0.84 | -2200% |
| Q2 2025 | -$0.74 | -1950% |
| Q1 2025 | -$0.68 | -6900% |
| Q4 2024 | -$0.66 | -3400% |
| Q3 2024 | $0.04 | 0% |
SY lost $0.28 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over SY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SY on profitability, with a higher operating margin.
SY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $75.6M | +33% |
| Q1 2026 | $64.6M | +45% |
| Q4 2025 | $68.2M | +23% |
| Q3 2025 | $58M | +4% |
| Q2 2025 | $56.8M | -7% |
| Q1 2025 | $44.6M | -6.6% |
| Q4 2024 | $55.4M | -5.5% |
| Q3 2024 | $55.8M | -3.5% |
SY's revenue has grown year over year for four quarters in a row: $76M last quarter, up 33% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -8.6% | +3.8 points |
| Q1 2026 | -13% | +1.2 points |
| Q4 2025 | -22% | +140 points |
| Q3 2025 | -19% | -20 points |
| Q2 2025 | -12% | -14 points |
| Q1 2025 | -15% | -3 points |
| Q4 2024 | -162% | -161 points |
| Q3 2024 | 1.3% | +1.8 points |
SY's operating margin was −8.6% last quarter, up 3.8 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SY on cash generation, producing positive trailing cash flow while its opponent burns cash.
SY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | $0 | $0 |
| Q4 2025 | -$45.3M | -$45.3M |
| Q3 2025 | $0 | $0 |
| Q2 2025 | $0 | $0 |
| Q1 2025 | $0 | $0 |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
| Q2 2024 | $0 | $0 |
SY's free cash flow was −$45M over the past year, against $0 the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +187K shares |
| 1 year | -0.1% | -75.7K shares |
| 3 years | +0.6% | +796K shares |
| 5 years | -6.3% | -8.9M shares |
| Available history | -6.2% | -8.6M shares |
SY has 131M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | $2.3M |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -73.4x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -4.1x | Net Cash |
| Q1 2024 | -6.3x | Net Cash |
| Q4 2023 | -5.1x | Net Cash |
| Q3 2023 | -5.3x | Net Cash |
| Q2 2023 | -17.6x | Net Cash |
| Q1 2023 | -141.9x | Net Cash |
SY has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 12.9 | Oversold |
SY's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SY PE vs Healthcare Sector
| Metric | SY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SY has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.29 | 15% below |
| 20 week MA | $2.22 | 13% below |
| 50 week MA | $2.50 | 22% below |
| 100 week MA | $2.35 | 17% below |
| 200 week MA | $1.88 | 3.2% above |
SY has fallen below most of its moving averages, though it's still 3.2% above its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SY on returns for 2026, with the stronger performance.
SY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.9 | $11.4 | -4.4% |
| 2021 | $11.4 | $3.13 | -73% |
| 2022 | $3.13 | $1.39 | -56% |
| 2023 | $1.39 | $1.29 | -7.2% |
| 2024 | $1.29 | $0.82 | -36% |
| 2025 | $0.82 | $2.63 | +221% |
| 2026 YTD | $2.63 | $1.94 | -26% |
SY's yearly returns have swung widely, from +221% in 2025 to −73% in 2021. It's down 26% so far in 2026.